All In Biotech

Drug Trial Radar · NCT03980730

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Last checked: Nov 19, 2026Latest source record: Jan 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

43

Actual

Start

Jun 27, 2019

Primary completion

Dec 1, 2020

Study completion Jan 29, 2021

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

Conditions

  • Alzheimer Disease

Interventions

  • AzeliragonDrug

    Azeliragon 5 mg capsule administered orally, once daily

  • PlaceboDrug

    Matching placebo capsule administered orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 : Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog14) at Month 6Time frame: Baseline to Month 6

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • Tucson Neuroscience Research

    Tucson, Arizona

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Charter Research

    Lady Lake, Florida

  • Alzheimer's Research and Treatment Center

    Lake Worth, Florida

  • ClinCloud

    Maitland, Florida

  • Synexus Clinical Research US

    Orlando, Florida

  • Emerald Coast Center for Neurological Disorders

    Pensacola, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • The Roskamp Institute

    Sarasota, Florida

  • Brain Matters Research

    Stuart, Florida

  • Emory Alzheimer's Clinical Research Unit

    Atlanta, Georgia

  • NeuroStudies.net LLC

    Decatur, Georgia

  • IU Health Partners, Adult Neurology Clinic

    Indianapolis, Indiana

  • Memory Center / Hattiesburg Clinic

    Hattiesburg, Mississippi

  • Millennium Psychiatric Associates

    St Louis, Missouri

  • The Cognitive and Research Center of New Jersey

    Springfield, New Jersey

  • Clarity Clinical Research

    East Syracuse, New York

  • Neurological Associates of Long Island

    Lake Success, New York

  • ANI Neurology dba Alzheimer's Memory Center

    Charlotte, North Carolina

  • Raleigh Neurology Associates

    Raleigh, North Carolina

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina

  • The Ohio State University

    Columbus, Ohio

  • Summit Research Network

    Portland, Oregon

  • Center for Cognitive Health

    Portland, Oregon

  • Okanagan Clinical Trials Ltd.

    Kelowna, British Columbia, Canada

  • True North Clinical Research Inc.

    Halifax, Nova Scotia, Canada

  • True North Clinical Research Inc.

    Kentville, Nova Scotia, Canada

  • Recherches Neuro-Hippocampe

    Ottawa, Ontario, Canada

  • Recherches Neuro-Hippocampe Inc.

    Gatineau, Quebec, Canada

  • Q&T Research Sherbrooke Inc

    Sherbrooke, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.